Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Quercetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.90 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.90 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.90 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 11/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.90 |
| ▸ | MAPT | P10636 | 8/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.90 |
| ▸ | RECQL | P46063 | 7/20 | 0.90 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.90 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.90 |
| ▸ | XDH | P47989 | 7/20 | 0.90 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.90 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.90 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.90 |
| ▸ | APP | P05067 | 6/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL30512465 | 1.00 | MEN1 (0.90) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL4473368 | 1.00 | MEN1 (0.90) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29351036 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL31507620 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29723041 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29353785 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL17629824 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL118425 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL19723 | 0.95 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL3786991 | 0.93 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580384-A | Fucoidin Process for producing phosphoric acid esters | 青岛职业技术学院 | 2024-09-03 | — | — | CN | claimed |
| CN-105902487-A | Injection pharmaceutical composition capable of improving stability of quercetin medication injection preparation | 成都易创思生物科技有限公司 | 2016-08-31 | — | — | CN | claimed |
| CN-105241938-A | Construction method and detection method of potassium ion nucleic acid aptamer photoelectrochemical sensor based on diluted magnetic semiconductor | YANCHENG INST TECHNOLOGY | 2016-01-13 | — | — | CN | claimed |
| WO-2009158007-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | claimed |
| CN-117298117-B | Medicine for treating chronic nephritis and composition thereof | 中国医学科学院药物研究所 | 2025-04-15 | — | — | CN | disclosed |
| CN-118580384-A | Fucoidin Process for producing phosphoric acid esters | 青岛职业技术学院 | 2024-09-03 | — | — | CN | disclosed |
| CN-118580384-A | Fucoidin Process for producing phosphoric acid esters | 青岛职业技术学院 | 2024-09-03 | — | — | CN | disclosed |
| CN-117298117-A | Medicine for treating chronic nephritis and composition thereof | 中国医学科学院药物研究所 | 2023-12-29 | — | — | CN | disclosed |
| WO-2018172942-A1 | QUERCETIN NANOPARTICLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018172942-A1 | QUERCETIN NANOPARTICLES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-09-27 | — | — | WO | disclosed |
| CN-105963247-A | Preparation method of injection medicine for improving stability of quercetin medicine injection preparation | 成都易创思生物科技有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105902487-A | Injection pharmaceutical composition capable of improving stability of quercetin medication injection preparation | 成都易创思生物科技有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2182957-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | Limerick BioPharma, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158031-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158007-A2 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009018338-A2 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069273-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | DPP4 1826/4885ADRA1A 1601/4885KDR 285/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | DPP4 121/4885ADRA1A 1276/4885KDR 3065/4885 |
| US-20100144612-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | DPP4 1826/4885ADRA1A 1601/4885KDR 285/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | DPP4 1826/4885ADRA1A 1601/4885KDR 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.